Track Syncona Limited — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Syncona Limited SYNC.L · Stock Open Syncona Limited in new tab

97.40 GBp
EPS
-0.15
P/B
0.23
ROE
-8.64
Beta
0.35
Target Price
202.00 GBp
Loading chart...
Key Metrics
Earnings dateJune 18, 2026
EPS-0.15
Book Value4.50
Price to Book0.23
Debt/Equity9.90
% Insiders1.705%
Growth
Revenue Growth-0.03%
Estimates
Forward P/E5.63
Forward EPS0.18
Target Mean Price202.00

DCF Valuation

Tweak assumptions to recompute fair value for Syncona Limited (SYNC.L)
Currency: GBp
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Syncona Limited Logo Syncona Limited Analysis (SYNC.L)

Is Syncona Limited a good investment? Syncona Limited (SYNC.L) is currently trading at 97.40 GBp. Market analysts have a consensus price target of 202.00 GBp. This suggests a potential upside from current levels.

Earnings Schedule: Syncona Limited is expected to release its next earnings report on June 18, 2026. The market consensus estimate for Forward EPS is 0.18.

Investor FAQ

Does Syncona Limited pay a dividend?

No, it does not currently pay a dividend.

What asset class is Syncona Limited?

Syncona Limited is classified as a Stock.

When is the next earnings date?

The next earnings date is projected to be June 18, 2026. The company currently has a trailing EPS of -0.15.

Company Profile

Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.

Trades
Dividend History paid per year (GBp)
Historical Dividends
Year Total Dividends
2019
2.30 GBp
July 15, 2019 2.3000
2018
2.30 GBp
July 16, 2018 2.3000
2017
2.30 GBp
Aug. 7, 2017 2.3000
2016
2.20 GBp
Aug. 19, 2016 2.2000
2015
2.10 GBp
Aug. 19, 2015 2.1000
2014
2.00 GBp
Sept. 10, 2014 2.0000
2013
1.00 GBp
Aug. 16, 2013 1.0000
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion